Function of Tumor Suppressors in Resistance to Antiandrogen Therapy and Luminal Epithelial Plasticity of Aggressive Variant Neuroendocrine Prostate Cancers

Function of Tumor Suppressors in Resistance to Antiandrogen Therapy and Luminal Epithelial Plasticity of Aggressive Variant Neuroendocrine Prostate Cancers

Combined loss of tumor suppressors (TSPs), PTEN, TP53, and RB1, is highly associated with small cell carcinoma of prostate phenotype. Recent genomic studies of human tumors as well as analyses in mouse genetic models have revealed a unique role for these TSPs in dictating epithelial lineage plastici...

Full description

Bibliographic Details
Main Authors: Rama Soundararajan, Ana M. Aparicio, Christopher J. Logothetis, Sendurai A. Mani, Sankar N. Maity
Format: Article
Language:English
Published: Frontiers Media S.A. 2018-03-01
Series:Frontiers in Oncology
Subjects:
tumor suppressors
neuroendocrine prostate cancer
lineage plasticity
therapy resistance
epithelial-to-mesenchymal transition
Online Access:http://journal.frontiersin.org/article/10.3389/fonc.2018.00069/full
Description
Summary:Combined loss of tumor suppressors (TSPs), PTEN, TP53, and RB1, is highly associated with small cell carcinoma of prostate phenotype. Recent genomic studies of human tumors as well as analyses in mouse genetic models have revealed a unique role for these TSPs in dictating epithelial lineage plasticity—a phenomenon that plays a critical role in the development of aggressive variant prostate cancer (PCa) and associated androgen therapy resistance. Here, we summarize recently published key observations on this topic and hypothesize a possible mechanism by which concurrent loss of TSPs could potentially regulate the PCa disease phenotype.
ISSN:2234-943X

Similar Items